Xingsheng Li1, Tim R Nagy1. 1. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Abstract
OBJECTIVE: To investigate the effects of the atypical antipsychotics drugs (AADs), olanzapine and risperidone, on femoral bone characteristics in female C57BL/6J mice. METHODS: Mice were treated with placebo or AADs (olanzapine or risperidone) for 3-4 weeks. Femoral cortical and trabecular bone characteristics were determined using micro-computed tomography. RESULTS: Olanzapine-treated mice tended to have lower trabecular bone volume (P = 0.088) and connectivity (P = 0.057) but no significant differences in bone density (P = 0.521) relative to controls. Risperidone-treated mice had significantly lower trabecular bone density (P = 0.001) and volume (P = 0.008), bone volume/total volume (P = 0.001), connectivity (P = 0.007), and trabecular number (P = 0.003) relative to controls. Cortical bone was not significantly affected by olanzapine or risperidone treatment. CONCLUSION: AADs inhibited trabecular bone accrual in C57BL/6J mice suggesting that alternative treatment options may need to be considered for the schizophrenia patient with potential osteoporosis risk.
OBJECTIVE: To investigate the effects of the atypical antipsychotics drugs (AADs), olanzapine and risperidone, on femoral bone characteristics in female C57BL/6J mice. METHODS:Mice were treated with placebo or AADs (olanzapine or risperidone) for 3-4 weeks. Femoral cortical and trabecular bone characteristics were determined using micro-computed tomography. RESULTS:Olanzapine-treated mice tended to have lower trabecular bone volume (P = 0.088) and connectivity (P = 0.057) but no significant differences in bone density (P = 0.521) relative to controls. Risperidone-treated mice had significantly lower trabecular bone density (P = 0.001) and volume (P = 0.008), bone volume/total volume (P = 0.001), connectivity (P = 0.007), and trabecular number (P = 0.003) relative to controls. Cortical bone was not significantly affected by olanzapine or risperidone treatment. CONCLUSION:AADs inhibited trabecular bone accrual in C57BL/6J mice suggesting that alternative treatment options may need to be considered for the schizophreniapatient with potential osteoporosis risk.
Entities:
Keywords:
cortical bone; olanzapine; risperidone; trabecular bone
Authors: Mary L Bouxsein; Stephen K Boyd; Blaine A Christiansen; Robert E Guldberg; Karl J Jepsen; Ralph Müller Journal: J Bone Miner Res Date: 2010-07 Impact factor: 6.741
Authors: Katherine J Motyl; Ingrid Dick-de-Paula; Ann E Maloney; Sutada Lotinun; Sheila Bornstein; Francisco J A de Paula; Roland Baron; Karen L Houseknecht; Clifford J Rosen Journal: Bone Date: 2011-08-11 Impact factor: 4.398
Authors: Mark B Cope; Xingsheng Li; Patricia Jumbo-Lucioni; Catherine A DiCostanzo; Wendi G Jamison; Robert A Kesterson; David B Allison; Tim R Nagy Journal: Physiol Behav Date: 2008-11-27
Authors: Oliver D Howes; Michael J Wheeler; Anna-Maria Meaney; Veronica O'Keane; Ignac Fogelman; Glen Blake; Robin M Murray; Shubulade Smith Journal: J Clin Psychopharmacol Date: 2005-06 Impact factor: 3.153